Antonio Guglietta - Böcker

Timothy Gaginella and Antonio Guglietta bring together hands-on experts to critically review the many promising new areas of gastrointestinal pharmacology at the molecular level. Key chapters discuss such major themes as cyclooxygenase-2 inhibitors, the complexities of nitric oxide pathways in the gut, and the influence of cytokines on inflammatory bowel disease, as well as new opportunities for pharmacotherapy, including peptide growth factors, achykinins - particularly substance P and neurokinins - cholecystokinin receptors, and serotonin. Also examined as possible sites for treating motility disorders and visceral pain are the opioid receptors residing in the gut, and the H3-receptor agonists for treating gut inflammation and pain. Drug Development: Molecular Targets for Gastrointestinal Disease provides a comprehensive review of today's molecular pharmacological approaches to the discovery and development of novel drugs for gastrointestinal and liver diseases.

Timothy Gaginella and Antonio Guglietta bring together hands-on experts to critically review the many promising new areas of gastrointestinal pharmacology at the molecular level. Key chapters discuss such major themes as cyclooxygenase-2 inhibitors, the complexities of nitric oxide pathways in the gut, and the influence of cytokines on inflammatory bowel disease, as well as new opportunities for pharmacotherapy, including peptide growth factors, achykinins-particularly substance P and neurokinins-cholecystokinin receptors, and serotonin. Also examined as possible sites for treating motility disorders and visceral pain are the opioid receptors residing in the gut, and the H3-receptor agonists for treating gut inflammation and pain. Drug Development: Molecular Targets for Gastrointestinal Disease provides a comprehensive review of today's molecular pharmacological approaches to the discovery and development of novel drugs for gastrointestinal and liver diseases.

In recent years, the area of pharmacotherapy of GI inflammation has witnessed important progress, with new drugs and therapeutic approaches being introduced. The volume reviews the pharmacotherapy of selected gastrointestinal inflammatory conditions chosen on the basis of their clinical importance and/or the areas where important and exciting progress has been made recently. Besides discussing current pharmacotherapy to treat the most important GI inflammation conditions, the book also indicates possible future therapeutic avenues likely to become available in a few years.The book is of interest to various sectors of the scientific community ranging from clinicians to pharmacologists and from biochemists to microbiologists, who will find it a useful tool for their clinical practice and research activity.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.